Testing for coronavirus
Syndromic testing

The future of infectious disease diagnostics

Patients with infectious illnesses often have signs and symptoms that are indicative of a disease, but that isn't specific enough to clinically distinguish what makes them ill. These patients are frequently given broad treatment, heavy monitoring and possibly unnecessary interventions. This puts a burden on healthcare systems, clinical labs and clinicians, and means patients aren't getting the best care possible.

We’re committed to helping healthcare workers like you navigate the challenges of diagnosing infectious diseases. That’s why we’ve developed an easy-to-use, automated diagnostic testing system that can help eliminate the guesswork and make your job easier. Our tests use multiplex PCR technology – also known as syndromic testing – that can quickly survey many different pathogens in a single patient sample. With syndromic testing, you get the answers you need, when you need them. And your patients get better care, faster.
New to rapid diagnostics with syndromic testing?
Find the information you need and learn how to incorporate syndromic testing into your diagnostic strategy.
Your lab in the palm of your hand 

What if you could monitor your diagnostic testing status anytime, anywhere? And get around-the-clock proactive technical support? It’s possible with QIAstat-Dx connectivity, powered by QIAsphere.*

Dr. Celestin Alexis Agbessi
“It changed our perception, our prescription habits, and it will change the way we work in the future. In the end, we gain money for both the community and the patients. That is really a big step forward.”

Celestin Alexis Agbessi, M.D., Bichat-Claude Bernard Hospital, Paris

Michelle Volk
“It’s hugely beneficial to be able to test for that wide range of pathogens. Ruling out COVID is helpful, but so is the chance to correctly identify other illnesses so physicians can treat the patients and their symptoms appropriately.”

Michelle Volk, CEO and president of Great Lakes Labs, Indiana, USA

Joshua Arant
“Our value to our patients and to our provider community has increased by bringing the QIAstat-Dx in-house.”

Joshua Arant, Founder and Chief Operations Officer, Mako Medical

Have a question about multiplex panel testing?
Get in touch with us today.
  1. Yalamanchili H, et al. (2018) Gastroenterol Hepatol, 14(11):646-652
  2. Binnicker M. Multiplex. (2015) J. Clin Microbiology, 53(12):3723-3728
  3. Macfarlane-Smith L, et al. (2018) Gastrointestinal Infections, 34(1):19-2
  4. Echavarria M, et al. (2018) J Clin Virol, 108:90–95
  5. Beal S G, et al. (2018) J Clin Microbiol, 18;56(1)
  6. Bouzid D, et al. (2020) J Hospital Infection, 337-338
  7. Iroh Tam PY, et al. (2017) Children (Basel), 4(1)
  8. Zhu et al. (2018) Clin Pediatr, 58(2): 185-190
  9. Martinez RM, et al. (2016) Clinical Virology Symposium, Poster #C-368

*Some features require a QIAstat-Dx Connectivity plan. Flexible plans are available to meet your lab’s needs.

Product claims may differ from country to country based on regulations and approvals. Contact your country representative for further details.

The QIAstat-Dx Viral Vesicular Panel is for research use only. The QIAstat-Dx Viral Vesicular Panel is run on the QIAstat-Dx Analyzer.

The QIAstat-Dx Analyzer 1.0 is intended for in vitro diagnostic use.

The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.

  • This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
  • This product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
  • This emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner